HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 28 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2020 | $27,000 | +575.0% | 38,308 | +172.4% | 0.00% | – |
Q1 2020 | $4,000 | 0.0% | 14,061 | +134.0% | 0.00% | – |
Q4 2019 | $4,000 | – | 6,009 | +909.9% | 0.00% | – |
Q3 2019 | $0 | -100.0% | 595 | -92.3% | 0.00% | – |
Q2 2019 | $13,000 | +30.0% | 7,695 | +79.8% | 0.00% | – |
Q1 2019 | $10,000 | -81.5% | 4,280 | -79.9% | 0.00% | – |
Q4 2018 | $54,000 | +1700.0% | 21,260 | +3473.1% | 0.00% | – |
Q3 2018 | $3,000 | -88.0% | 595 | -92.1% | 0.00% | – |
Q2 2018 | $25,000 | +1150.0% | 7,531 | +1452.8% | 0.00% | – |
Q1 2018 | $2,000 | +100.0% | 485 | 0.0% | 0.00% | – |
Q4 2017 | $1,000 | -83.3% | 485 | -86.2% | 0.00% | – |
Q3 2017 | $6,000 | +100.0% | 3,524 | +234.0% | 0.00% | – |
Q2 2017 | $3,000 | -97.8% | 1,055 | -94.7% | 0.00% | – |
Q1 2017 | $137,000 | +878.6% | 19,773 | +216.8% | 0.00% | – |
Q3 2016 | $14,000 | -80.8% | 6,242 | -76.7% | 0.00% | – |
Q2 2016 | $73,000 | +180.8% | 26,749 | +350.7% | 0.00% | – |
Q4 2015 | $26,000 | +420.0% | 5,935 | +1261.2% | 0.00% | – |
Q2 2015 | $5,000 | – | 436 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
PERKINS CAPITAL MANAGEMENT INC | 2,426,300 | $802,000 | 0.74% |
Cowen Prime Services LLC | 1,411,500 | $466,000 | 0.23% |
GSA CAPITAL PARTNERS LLP | 1,205,873 | $398,000 | 0.07% |
Nantahala Capital Management | 5,113,958 | $1,690,000 | 0.05% |
HighMark Wealth Management LLC | 80,000 | $26,000 | 0.02% |
Kalos Management, Inc. | 72,858 | $24,000 | 0.01% |
Qube Research & Technologies Ltd | 585,187 | $193,000 | 0.00% |
WINTON GROUP Ltd | 190,146 | $63,000 | 0.00% |
Ironwood Financial, llc | 1,571 | $1,000 | 0.00% |
Virtu Financial LLC | 12,049 | $4,000 | 0.00% |